Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Multiple Cancer Types

The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). The secondary objective is to evaluate evidence of clinical efficacy associated with BAY2402234 in patients with AML (defined as Complete remission, Complete remission with partial hematologic recovery), and MDS (defined as hematological improvement).
Hematologic, Leukemia, Myelodysplastic Syndrome, Phase I
I
Savona, Michael
NCT03404726
VICCHEMP1826

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: